Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine

Vaccine

Volumn 25, Issue 21, 2007, Pages 4324-4333

  Fraser, Christophe ^a   Tomassini, Joanne E ^b   Xi, Liwen ^b   Golm, Greg ^b   Watson, Michael ^c   Giuliano, Anna R ^d   Barr, Eliav ^b   Ault, Kevin A ^e  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

^c SANOFI PASTEUR   (France)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody duration; HPV 16; Modeling; Prophylactic HPV vaccine; VLP

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOLOGICAL MEMORY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVIX DYSPLASIA; VACCINATION; VIRUS INFECTION; VIRUS LIKE AGENT; WART VIRUS;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; FEMALE; FOLLOW-UP STUDIES; HUMAN PAPILLOMAVIRUS 16; HUMANS; MODELS, IMMUNOLOGICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TIME FACTORS; UTERINE CERVICAL NEOPLASMS; VACCINES, VIROSOME;

EID: 34247340959     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.02.069     Document Type: Article

References (38)

1. Ferlay J., Bray F., and Pisani P. GLOBOCAN 2002: Cancer Incidence, Mortality, and Prevalence Worldwide. IARC CancerBase No. 5, version 2.0 (2004), IARC Press, Lyon
2. Clifford G., Franceschi S., Diaz M., Muñoz N., and Villa L.L. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 24S3 (2006) S326-S334
3. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., and Shah K.V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55 4 (2002) 244-265
4. Miller A.B., Sankaranarayanan R., Bosch F.X., and Sepulveda C. Can screening for cervical cancer be improved, especially in developing countries?. Int J Cancer 107 3 (2003) 337-340
5. Brown D.R., Fife K.H., Wheeler C.M., Koutsky L.A., Lupinacci L.M., Railkar R., et al. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine 22 21-22 (2004) 2936-2942
6. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 21 (2002) 1645-1651
7. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 5 (2005) 271-278
8. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 9447 (2004) 1757-1765
9. Mao C., Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Wiley D.J., et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107 1 (2006) 18-27
10. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 367 9518 (2006) 1247-1255
11. Villa L.L., Costa R.L.R., Petta C.A., Andrade R.P., Paavonen J., Iversen O., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus (Hpv) Types 6/11/16/18 L1 virus-like particle (Vlp) vaccine through five years of follow-up. Br J Cancer 95 11 (2006) 1459-1466
12. Mossong J., Nokes D.J., Edmunds W.J., Cox M.J., Ratnam S., and Muller C.P. Modeling the impact of subclinical measles transmission in vaccinated populations with waning immunity. Am J Epidemiol 150 11 (1999) 1238-1249
13. Bovier P.A., Bock J., Loutan L., Farinelli T., Glueck R., and Herzog C. Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. J Med Virol 68 4 (2002) 489-493
14. Lee M.S., Chien L.J., Yueh Y.Y., and Lu C.F. Measles seroepidemiology and decay rate of vaccine-induced measles IgG titers in Taiwan, 1995-1997. Vaccine 19 32 (2001) 4644-4651
15. Mossong J., O'Callaghan C.J., and Ratnam S. Modelling antibody response to measles vaccine and subsequent waning of immunity in a low exposure population. Vaccine 19 4-5 (2000) 523-529
16. Van Herck K., and Van Damme P. Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. J Med Virol 63 1 (2001) 1-7
17. Teunis P.F., van der Heijden O.G., de Melker H.E., Schellekens J.F., Versteegh F.G., and Kretzschmar M.E. Kinetics of the IgG antibody response to pertussis toxin after infection with B. pertussis. Epidemiol Infect 129 3 (2002) 479-489
18. Gesemann M., and Scheiermann N. Quantification of hepatitis B vaccine-induced antibodies as a predictor of anti-HBs persistence. Vaccine 13 5 (1995) 443-447
19. Honorati M.C., Palareti A., Dolzani P., Busachi C.A., Rizzoli R., and Facchini A. A mathematical model predicting anti-hepatitis B virus surface antigen (HBs) decay after vaccination against hepatitis B. Clin Exp Immunol 116 1 (1999) 121-126
20. Macallan D.C., Wallace D.L., Zhang Y., Ghattas H., Asquith B., de Lara C., et al. B-cell kinetics in humans: rapid turnover of peripheral blood memory cells. Blood 105 9 (2005) 3633-3640
21. Manz R.A., Hauser A.E., Hiepe F., and Radbruch A. Maintenance of serum antibody levels. Annu Rev Immunol 23 (2005) 367-386
22. Bernasconi N.L., Traggiai E., and Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298 (2002) 2199-2202
23. Glass K., and Grenfell B.T. Antibody dynamics in childhood diseases: waning and boosting of immunity and the impact of vaccination. J Theor Biol 221 1 (2003) 121-131
24. Glass K., and Grenfell B.T. Waning immunity and subclinical measles infections in England. Vaccine 22 29-30 (2004) 4110-4116
25. Versteegh F.G., Mertens P.L., de Melker H.E., Roord J.J., Schellekens J.F., and Teunis P.F. Age-specific long-term course of IgG antibodies to pertussis toxin after symptomatic infection with Bordetella pertussis. Epidemiol Infect 133 4 (2005) 737-748
26. Palker T.J., Monteiro J.M., Martin M.M., Kakareka C., Smith J.F., Cook J.C., et al. Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles. Vaccine 19 27 (2001) 3733-3743
27. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 102 5A (1997) 3-8
28. Villa L.L., Ault K.A., Guilianok A.R., Cost R.L.R., Petta C.A., Andrade R.P., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 24 (2006) 5571-5583
29. Zinkernagel R.M., and Hengartner H. On immunity against infections and vaccines: credo 2004. Scand J Immunol 60 1-2 (2004) 9-13
30. Stanley M. Immune responses to human papillomavirus. Vaccine 24 Suppl. 1 (2006) S16-S22
31. Ho G.Y., Studentsov Y.Y., Bierman R., and Burk R.D. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 13 1 (2004) 110-116
32. Xi L.F., Carter J.J., Galloway D.A., Kuypers J., Hughes J.P., Lee S.K., et al. Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort of female university students. Cancer Epidemiol Biomarkers Prev 11 4 (2002) 343-351
33. Shah K.V., Viscidi R.P., Alberg A.J., Helzlsouer K.J., and Comstock G.W. Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix. Cancer Epidemiol Biomarkers Prev 6 4 (1997) 233-237
34. Carter J.J., Koutsky L.A., Hughes J.P., Lee S.K., Kuypers J., Kiviat N., et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 181 6 (2000) 1911-1919
35. ®. 9th Annual Vaccine Research Conference in Baltimore (2006)
36. Pinto L.A., Edwards J., Castle P.E., Harro C.D., Lowy D.R., Schiller J.T., et al. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis 188 2 (2003) 327-338
37. Steele J.C., Mann C.H., Rookes S., Rollason T., Murphy D., Freeth M.G., et al. T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia. Br J Cancer 93 2 (2005) 248-259
38. Wilson J.N., Nokes D.J., and Dimmock N.J. Analysis of the relationship between immunogenicity and immunity for viral subunit vaccines. J Med Viol 64 (2001) 560-568